Misplaced Pages

Camlipixant

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Camlipixant
Clinical data
Other namesBLU-5937
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • methyl (2S)-2--7-methylimidazopyridin-3-yl]methyl]morpholine-4-carboxylate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC23H24F2N4O4
Molar mass458.466 g·mol
3D model (JSmol)
SMILES
  • CC1=CC2=NC(=C(N2C=C1)C3CN(CCO3)C(=O)OC)C4=C(C=C(C=C4F)C(=O)NC)F
InChI
  • InChI=1S/C23H24F2N4O4/c1-13-4-5-29-18(11-15-12-28(6-7-33-15)23(31)32-3)21(27-19(29)8-13)20-16(24)9-14(10-17(20)25)22(30)26-2/h4-5,8-10,15H,6-7,11-12H2,1-3H3,(H,26,30)/t15-/m0/s1
  • Key:SEHLMRJSQFAPCJ-HNNXBMFYSA-N

Camlipixant is an investigational new drug that is being evaluated for the treatment of chronic cough. It is a P2X3 receptor antagonist.

See also

References

  1. "Camlipixant - BELLUS Health". AdisInsight. Springer Nature Switzerland AG.
  2. Garceau D, Chauret N (June 2019). "BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration". Pulmonary Pharmacology & Therapeutics. 56: 56–62. doi:10.1016/j.pupt.2019.03.007. PMID 30902655.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: